COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR UNRESECTABLE METASTATIC MELANOMA AFTER PROGRESSION WITH IPILIMUMAB IN ENGLAND

被引：7
|
作者：
Marriott, E. [1 ]
Praet, C. [2 ]
Aguiar-Ibanez, R. [2 ]
Pellissier, J. [3 ]
Xu, R. [3 ]
Wang, J. [3 ]
机构：
[1] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[2] Merck Sharp & Dohme Ltd, Hoddesdon, England
[3] Merck & Co Inc, St Charles, IL USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1150
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN134
引用
收藏
页码：A453 / A453
页数：1
相关论文
共 50 条
  • [1] COST EFFECTIVENESS OF PEMBROLIZUMAB AND IPILIMUMAB IN ADVANCED MELANOMA
    Lu, T.
    Hay, J. W.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [2] Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China
    Tang, Wen-Xi
    Shao, Rong-Jie
    Wang, Jingshu
    Scherrer, Emilie
    Ma, Ai-Xia
    Aguiar-Ibanez, Raquel
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 27 : 99 - 107
  • [3] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) VERSUS IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Wang, J.
    Chabot, I
    El-Hadi, W.
    Xu, R.
    Pellissier, J.
    Iliopoulos, I.
    VALUE IN HEALTH, 2016, 19 (03) : A153 - A154
  • [4] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA PREVIOUSLY TREATED WITH IPILIMUMAB IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
  • [5] Cost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia
    Bohensky, M. A.
    Kim, H.
    Gorelik, A.
    Liew, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [6] Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naive Patients with Advanced Melanoma in the United States
    Wang, Jingshu
    Chmielowski, Bartosz
    Pellissier, James
    Xu, Ruifeng
    Stevinson, Kendall
    Liu, Frank Xiaoqing
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 158 - 158
  • [7] MODELLING THE COST-EFFECTIVENESS OF IPILIMUMAB FOR PREVIOUSLY-TREATED, METASTATIC MELANOMA
    Lee, D.
    Winn, B.
    Lebmeier, M.
    Batty, A.
    VALUE IN HEALTH, 2012, 15 (07) : A423 - A423
  • [8] COST-EFFECTIVENESS ANALYSIS OF IPILIMUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE MALIGNANT MELANOMA IN SCOTLAND
    Lee, D.
    Porter, J.
    Hatswell, A. J.
    Hertel, N.
    Walker, A.
    VALUE IN HEALTH, 2014, 17 (07) : A549 - A549
  • [9] COST-EFFECTIVENESS OF IPILIMUMAB FOR PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED METASTATIC MELANOMA IN SPAIN
    Aceituno, S.
    Canal, C.
    Paz, S.
    Gonzalez, P.
    Marquez-Rodas, I
    VALUE IN HEALTH, 2014, 17 (07) : A631 - A631
  • [10] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR TREATING PREVIOUSLY UNTREATED METASTATIC MELANOMA PATIENTS IN FRANCE
    Godard, C.
    Wang, J.
    Gauthier, A.
    Levy-Bachelot, L.
    Annemans, L.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
12345